Narrative exposure therapy in victims of trafficking and other forced migrants

Treating Post-traumatic Stress Disorder in Victims of Trafficking and other Forced Migrants using Narrative Exposure Therapy: A Pilot Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN95136302

Enrollment

Registered

2017-02-08

Start date

2017-03-01

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic Stress Disorder in victims of trafficking and other forced migrants. Mental and Behavioural Disorders Post-traumatic Stress Disorder

Interventions

Eligible participants will be randomized to either Narrative Exposure Therapy (N=15-20) or the waitlist control group (N=15-20). Randomization will be performed using stratification for victims of tra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Post-traumatic Stress disorder according to DSM 5 2. A history of human trafficking or other human rights abuses 3. Provision of informed consent

Exclusion criteria

Exclusion criteria: Any internal or external factors that indicate the person is not stable enough for trauma-focused treatment to be appropriate (in accordance with NICE Guidelines for PTSD, 2005). This will include comorbid psychosis, substance misuse and high risk of suicide and/or self-harm, as well as destitution, street homelessness, risk of imminent removal from the UK and the inability of parents to organise childcare due to safeguarding and attendance issues.

Design outcomes

Primary

Measure	Time frame
Post-traumatic Stress Disorder rate is measured using the Clinician-administered PTSD Scale (CAPS-5) and the Post-traumatic Stress Disorder Checklist (PCL-5) at baseline, midway through treatment (after 8 sessions), after 16 sessions, at the end of treatment (if this is more than 16 sessions), and at three, six and twelve month follow-up.	—

Secondary

Measure	Time frame
1. Depression is measured using Patient Health Questionnaire (PHQ-9) 2. Anxiety is measured using Generalised Anxiety Disorder (GAD-7) 3. Dissociation is measured using Shutdown Dissociation Scale (ShuDis) 4. Levels of generalized distress is measured using Clinical Outcomes in Routine Evaluation (CORE) 5. Self-Compassion using the Self-compassion Scale short from (SCS-SF) 6. Rumination is measured using Preservative Thinking Questionnaire (PTQ) and the Self-Critical Rumination Scale (SCRS) 7. Self-esteem is measured using Rosenberg Self-Esteem 8. General daily functioning and satisfaction is measured using Work and Social Adjustment Scale (WASA) All outcomes will be measured at baseline, midway through treatment (after 8 sessions), after 16 sessions, at the end of treatment (if this is more than 16 sessions), and at three, six and twelve month follow-up.	—

Measure

Time frame

1. Depression is measured using Patient Health Questionnaire (PHQ-9) 2. Anxiety is measured using Generalised Anxiety Disorder (GAD-7) 3. Dissociation is measured using Shutdown Dissociation Scale (ShuDis) 4. Levels of generalized distress is measured using Clinical Outcomes in Routine Evaluation (CORE) 5. Self-Compassion using the Self-compassion Scale short from (SCS-SF) 6. Rumination is measured using Preservative Thinking Questionnaire (PTQ) and the Self-Critical Rumination Scale (SCRS) 7. Self-esteem is measured using Rosenberg Self-Esteem 8. General daily functioning and satisfaction is measured using Work and Social Adjustment Scale (WASA) All outcomes will be measured at baseline, midway through treatment (after 8 sessions), after 16 sessions, at the end of treatment (if this is more than 16 sessions), and at three, six and twelve month follow-up.

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 14, 2026